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Abstract
Mice xenotransplanted with human cells and/or expressing
human gene products (also known as “humanized mice”) reca-
pitulate the human evolutionary specialization and diversity of
genotypic and phenotypic traits. These models can provide a
relevant in vivo context for understanding of human-specific
physiology and pathologies. Humanized mice have advanced
toward mainstream preclinical models and are now at the fore-
front of biomedical research. Here, we considered innovations
and challenges regarding the reconstitution of human immunity
and human tissues, modeling of human infections and cancer,
and the use of humanized mice for testing drugs or regenera-
tive therapy products. As the number of publications exploring
different facets of humanized mouse models has steadily
increased in past years, it is becoming evident that standard-
ized reporting is needed in the field. Therefore, an international
community-driven resource called “Minimal Information for
Standardization of Humanized Mice” (MISHUM) has been
created for the purpose of enhancing rigor and reproducibility
of studies in the field. Within MISHUM, we propose comprehen-
sive guidelines for reporting critical information generated using
humanized mice.
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Glossary
ADCC antibody-dependent cellular cytotoxicity, is an
immune defense mechanism whereby effector
cells such as NK cells lyses target cells that
have been bound by specific antibodies
AML acute myeloid leukemia
ART anti-retroviral therapy
BDBV Bundibugyo ebolavirus
BiTE bispecific T-cell engagers is a registered
trademark for a class of recombinant bispecific
monoclonal antibodies which bind to the CD3
receptor and to a tumor-specific antigen
BLT bone marrow-liver-thymus
BM bone marrow
bNAbs broadly neutralizing antibodies are antibodies
capable of neutralizing different types of viral
strains
BRGF Balb/c Rag2/ Il2rg/ Flt3/
BRGSA2DR2 BRGS mice expressing human HLA-A2 and DR2
transgenes
CAR chimeric antigen receptor
CB cord blood
CCR5 chemokine receptor targeted by R5 tropic HIV
strains
CD40L CD40 ligand
CDX cell line-derived xenograft
CRS cytokine release syndrome is a systemic
inflammatory response that can be triggered
by infections, drugs, and cell therapies
DCs dendritic cells
DRAG mouse strain expressing a human HLA-DR gene
and derived from the NRG strain
EBOV Zaire ebolavirus
EBV Epstein–Barr virus
ES cell embryonic stem cell
FAH/ knock-out for the fumarylacetoacetate
hydrolase gene
Flt3L Flt3 ligand
G-CSF granulocyte colony-stimulating factor
GITR glucocorticoid-induced TNFR family-related
protein
GM-CSF granulocyte–macrophage colony-stimulating
factor
gp glycoprotein
GVHD graft-versus-host disease
HAdV2 human adenovirus 2
HBV hepatitis B virus
HCMV human cytomegalovirus
HCT HSC transplantation is a routine clinical
procedure performed with hematopoietic stem
cells from the patient (autologous) or from a
donor (allogeneic) with the purpose of
combating malignancies or correcting defects
of the immune system
HCV hepatitis C virus
Hematopoiesis is the differentiation of different blood cell
lineages derived from multipotent
hematopoietic stem cells (HSCs)
HIS human immune system
HIV human immunodeficiency virus
HLAs human leukocyte antigens
HSCs human hematopoietic stem cells
HSPCs hematopoietic/stem/progenitor cells
HSPCs hematopoietic/stem/progenitor cells
HSVtk herpes simplex virus type 1 thymidine kinase
huPBL human peripheral blood lymphocyte
IFN interferon
IgG immunoglobulin G
IgM immunoglobulin M
IL-2 interleukin 2
Il2rg interleukin 2 (IL-2) receptor common gamma
chain
IL-3 interleukin 3
IO Immuno-oncology
iPS cell induced pluripotent stem cells
LDL low-density lypoprotein
Lin lineage negative
lymphomagenesis is the development of malignancies derived
from lymphocytes such as B and T cells
mAb monoclonal antibodies
M-CSF macrophage colony-stimulating factors
MDS myelodysplastic syndrome
MERS Middle East respiratory syndrome-related
coronavirus
MHC major histocompatibility complex
MISHUM minimal information for standardization of
humanized mice
MISTRG-6 mouse strain expressing macrophage colony-
stimulating factors (M-CSF), IL-3, IL-6, GM-CSF,
and thrombopoietin (TPO)
MSCs mesenchymal stromal cells
Myelo-ablated mice are mice treated with irradiation or
chemotherapy in order to decrease the bone
marrow activity in order to improve the
engraftment of transplanted stem cells
Myelodysplasia is an abnormal accumulation of immature
blood cells in the bone marrow
Myelofibrosis is the replacement of the bone marrow with
scar tissue due to proliferation of immature
blood cells
NASH non-alcoholic steatohepatitis
NIH National Institutes of Health
NK natural killer
NOD Non-obese diabetic
NOG NOD.Cg-PrkdcscidIl2rgtm1Sug/Jic
NRGF NOD-Rag1/ Il2rg/ Flk2/
NRG NOD-Rag1tm1Mom Il2rgtm1Wjl/SzJ
NSG NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
PBMCs peripheral blood mononuclear cells
PD-1 programmed death receptor 1
PD-L1 PD-1 ligand 1
PDX-MI PDX Model Minimal Information standard
PDX patient-derived xenograft
PIRF POR//Il2rg//Rag2//FAH/
Rag1 recombination activating gene 1
Rag2 recombination activating gene 2
RESTV Reston ebolavirus
RSV Respiratory syncytial virus
SC-beta stem cell-derived human beta cells
SCF stem cell factor
scid mice CB17-Prkdcscid severely compromised
immunodeficient
SCID-hu SCID-humanized
SHIV simian and human immunodeficiency virus
Sirpa signal regulatory protein alpha
SUDV Sudan ebolavirus
T1D type 1 diabetes
TAFV Tai Forest ebolavirus
TCB T-cell bispecific antibodies
TCRs T-cell receptors
Tim-3 T-cell immunoglobulin and mucin domain-
containing protein 3
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Studies of human stem cell engraftment, hematopoiesis,
and immunity
Studies using immunocompetent mice have provided critical
insights into the development and regulation of hematopoiesis and
immunity. However, such studies do not always reflect responses in
humans because of multiple species-specific differences. Therefore,
mice developing components of the human immune system (HIS)
mice were created. These models have provided tools for the under-
standing of human hematopoiesis and immunity in vivo and to test
new therapies or vaccines without incurring risks to patients.
The simplest engraftment method is the adoptive administration
of human peripheral blood mononuclear cells (PBMCs) into severely
immunodeficient mice (Fig 1A, Table 1). Since the adoptive human
T cells react forcefully against the xenogeneic major histocompati-
bility complex (MHC) class I and II expressed by mouse tissues, this
so-called “huPBL” model faces the hardship of fulminant xenograft
graft-versus-host disease (GVHD) occurring 2–4 weeks after PBMC
transfer. These models have limited applicability to follow specific
antigenic responses, but can be used to test human immunosuppres-
sive agents. Improvement of the huPBL model has been described
with novel mouse strains lacking mouse MHC class I and II,
resulting in lower occurrences of GVHD (Yaguchi et al, 2018; Brehm
et al, 2019).
A more complex approach covered here in detail is the
hematopoietic stem cell transplantation (HCT) of preconditioned
immunodeficient mice with human hematopoietic stem cells
(HSCs). Despite the full mismatch between the human leukocyte
antigens (HLA) expressed on the human hematopoietic cells and the
mouse MHC expressed on tissues, HCT leads to “fully” humanized
HIS models (Fig 1A, Table 1). Human HSCs can differentiate into
multiple human hematopoietic lineages, giving rise to mature leuko-
cytes, including several lineages of the human immune system.
Robust engraftment with human hematopoietic and lymphoid cells
was pioneered back in 1988 with the description of the CB17-
Prkdcscid severely compromised immunodeficient (scid) strain
engrafted with human fetal liver hematopoietic cells and autologous
thymic tissues (McCune et al, 1988). This SCID-humanized (SCID-
hu) system showed initially only a transient presence of human T
cells and human immunoglobulin G (IgG) in the circulation. The
critical relevance of the strain background for engraftment success
of human cells was later appreciated when it was observed that
non-obese diabetic (NOD)-scid mice had a much higher capacity to
support human HSC engraftment. This was elucidated to be due to
the expression of a human-like signal regulatory protein alpha
(Sirpa) allele in the NOD strain, popularly known as the “don’t eat
me signal”, bypassing phagocytosis of human cells by mouse
macrophages (Takenaka et al, 2007; Shultz et al, 2012). Targeting
the interleukin 2 (IL-2) receptor common gamma chain (Il2rg)
resulted in the absence of mouse natural killer (NK) cell activity as
well as ablation of T and B lymphocyte lineages. In addition, the
development of mice lacking the expression of recombination acti-
vating gene 1 (Rag1)/ and Rag2/ provided radioresistant mouse
models lacking mature host T cells as well as B cells (Shultz et al,
2007). Currently, there are approximately 50 diverse humanized
mouse models available from biorepositories. Most of these models
are homozygous for the scid, Il2rg, Rag1, or Rag2 mutations and
express the NOD or human Sirpa allele. The NOD-scid IL2rg(/)
(NSG), the NOD-Rag1/ IL2rg/ (NRG), and the NOD/Shi-scid
IL2rg(/) (NOG) are broadly used strains for xenografting a large
variety of human cells, but several other strains are prospering (for
recent reviews, see Shultz et al, 2019; Allen et al, 2019).
It is important to be thoughtful also about the nature of the
human HSCs. Although humans and mice differ greatly in their
biological characteristics, human HSCs can essentially engraft in
myelo-ablated or irradiated mice and reside in the mouse bone
marrow (BM) niche. This HCT approach opened several doors for
the understanding of the basic properties for long-term durable
repopulation of human HSCs. As sources of human HSCs, cord
blood (CB) or fetal liver are mostly used, as they have high frequen-
cies of HSCs. Generally, a range of 1 × 104–105 isolated HSCs is
administered per mouse in order to enable efficient human
hematopoietic engraftment and long-term reconstitution. Several
laboratories have opted to use fetal tissues due to the higher abun-
dance in the numbers of HSCs, which can be explored to generate
larger cohorts of humanized mice (n = 30–40) compared with cord
blood (n = 10–20). Some groups have tried to overcome this limita-
tion by pooling HSCs from several donors, but upon development of
immune systems that are not HLA-matched, once the T cells
develop, allograft reactions among donors can complicate the analy-
ses of the immune responses. Additionally, it is important to take
into consideration that HSCs in fetal and neonatal tissues may be
intrinsically different regarding the stage of the hematopoietic devel-
opment. Further, it is important to consider ethical constraints and
difficulties in procurement of human fetal tissues. In fact, the US
National Institutes of Health (NIH) is currently supporting investiga-
tors to seek and develop humanized mouse models that do not rely
on human fetal tissues (Allen et al, 2019).
Human HSC cell surface markers have been used to allow their
identification, purification, and analyses, in order to define the HSC
populations with highest engraftment and/or repopulation capacity.
Xenotransplantation of human CD34+ HSCs into preconditioned
immunodeficient mice is the most broadly used procedure to gener-
ate HIS mice, and this approach is corroborated by the clinical
evidence that transplantation with human-enriched CD34+
hematopoietic/stem/progenitor cells (HSPCs) is a salvage procedure
when the HLA is not optimally matched between patients and
donors. Remarkably, a defined CD93hi sub-fraction within the
lineage negative (Lin) CD34 CD38 cell present in CB has high
repopulating capacity in NOD-scid mice (Danet et al, 2002). CD49f
is an adhesion molecule serving as a HSC marker and intra-femoral
injection of single CD49f+ cells into female NSG mice can generate
TK-NOG NOG mice expressing transgenic herpes
simplex virus type 1 thymidine kinase (HSVtk)
under the albumin promoter (NOD.Cg-
PrkdcscidIl2rgtm1SugTg(Alb-Tk)7-2/ShiJic)
TPO Thrombopoietin
Tregs regulatory T cells
TSLP thymic-stromal-cell-derived lymphopoietin
uPA urokinase-type plasminogen activator
expressed under the albumin promoter
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Human materials Immunodeficient mouse strain characteristics and
delivery routes in the adult or neonatal mouse
Analyses performed for different
types of humanized mouse models
A HUMAN IMMUNITY
• Fetal liver HSCs,
 liver tissue | organoid
 thymic tissue | organoid
• CB CD34+ HCT
• Adult CD34+ HCT
• huPBL
• Human
 cytokines
• HLAs
• Adoptive DCs
• HSC engraftment
• Long term hematopoiesis
• Graft-versus-host disease
• Human myeloid cells,
 NK cells,
 T cells,
 B cells
• Mature, functional and 
 antigen-specific cells
Intravenous Intraperitoneal
Intrahepatic
Intrasplenic
Intrafemoral
Under renal
capsule
D HUMAN MALIGNANCIES
• Liquid or solid tumor cell line (CDX) or
• Patient derived xenograft (PDX)
Preclinical trials
• Drugs
• Cell therapy
• Weight loss
• Leukemia or tumor growth
• Metastases
• Mutational variation/selection
• Tumor microenvironment
• Therapeutic drug treatment
B HUMAN METABOLISM
• iPSC
• ES cell-derived
 tissue
• Fetal liver tissue
• Adult liver tissue
• Preconditioning
• Regeneration
 model
• Engraftment
• Degree of chimerism
 (initial and over time)
• Tissue-specific functional
 validation
• Human metabolism
• Autoimmunity/diabetes
• Gut tissue
• Kidney tissue
• Pancreatic islets
• Other tissues
C HUMAN INFECTIONS
• EBV
• HCMV
• KSHV
• HIV
• HBV
• HCV
• ZIKV
• DENV
Preclinical trials
• Drugs
• Cell therapy
• Vaccination
• Weight loss
• Human cell depletion
• Virus induced tumors
• T cell/B cell immune responses
• Mutational variation
• Protective vaccination
• Drug treatment
• Adenoviruses
• Ebolaviruses
• Coronaviruses
• Hantaviruses
• Salmonella typhi
• Mycobacterium tuberculosis
• Plasmodium falciparum
• Toxoplasma gondii
Intravenous
Intraperitoneal
Intrarectal
Intranasal
Intrasplenic
Intrasplenic
Under renal
capsule
Intrahepatic
Intra human scaffold 
E HUMAN IMMUNO-ONCOLOGY
• Liquid or solid tumor cell line (CDX) or 
• Patient derived xenograft (PDX)
+ CB CD34+ HCT
 or
+ Autologous/allogeneic huPBL
+ CAR-T cells
+ NK cells
+ mAbs
+ BITE engagers
Preclinical trials
• Drugs
• Cell therapy
• Vaccination
• Weight loss
• Leukemia or tumor growth
• Metastases
• Mutational variation/selection
• Tumor microenvironment
• Therapeutic immune response
• Cytokine release syndrome
Intravenous
Under renal
capsule
Intrafemoral
Subcutaneous
Orthotopic
Intra mammary
fat pad 
Intravenous
Under renal
capsule
Intrafemoral
Subcutaneous
Orthotopic
Intra mammary
fat pad 
©
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Figure 1. Development and applications of humanized mouse models.
Schematic representation of the human materials (in blue), immunodeficient mouse strain characteristics and handling (black), and analyses performed (red) for different
types of humanized mouse models: (A) human immunity; (B) human metabolism; (C) human infections; (D) human malignancies; (E) human immuno-oncology.
Abbreviated items are spelled out in the glossary.
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Table 1. Checklist as a guideline for reporting the “Minimal
Information for Standardization of Humanized Mice” (MISHUM).
MISHUM Section 1: human donor
• *Ethical approval and informed consent
• *(Gestational) age
• Sex
• Ethnic origin
• Human leukocyte antigens (HLA-A, B, C, DR)
• Known latent viral infections (EBV, HCMV, HIV, HCV, LCMV, HBV)
• Exome sequence if available
MISHUM Section 2: human cells or tissues
• *Cell lines (mycoplasma tested or other tests)
• *Cell lines or primary cells/tissue available through academic collections
and material transfer agreement/publicly available through commercial
repositories
• *huPBL: Whole blood, PBMC
• *HSC: obtained from fetal liver, cord blood, G-CSF mobilized adult
donors, bone marrow
• Hepatocytes (non parenchymal cells)
• Primary patient tumors (isolation or collection method)
• *Density fractionation (e.g., by Ficoll)
• *Surface markers for positive cell isolation (magnetic beads or sorting)
• *Surface markers for cell depletions (magnetic beads or sorting)
• *Single donor or pooled
• *Fresh or cryopreserved
• *Dose as viable cell numbers
• * Dose of tissue by weight
• *Genetic modifications
• *Genetic reprogramming (e.g., iPSC)
• *Ex vivo expansion
• *Ex vivo activation
• *Use of scaffolds for 3D culture
• *Organoids
• Known if latently infected with pathogens
MISHUM Section 3: mouse recipient
• *Institutional approval and approval number
• *Strain/source/publicly available or material transfer agreement/stock
number
• *Human transgenes/knock-in
• *Knock-out of mouse genes
• *Sex
• *Age (weeks)
• Health reports
• Microbiota
MISHUM Section 4: mouse handling
• *Anesthesia (local, general, type and dose)
• *Preconditioning (radiation dose/schedule for pharmacologic myeloabla-
tion or liver cell death)
• *Route of injections (intravenous, intra-peritoneal, intra-femoral, intra-
liver, intra-splenic)
• *Surgical implantation (under kidney capsule, intradermal, in mammary
fat pad)
• *Collection of blood (intravenous, facial vein, cardiac puncture)
• *Administration of recombinant cytokines (vendor, units per weight,
route)
• *Administration of vectors (type, dose, route)
• Non-invasive optical imaging methods (fluorescence, bioluminescence
substrate, dose, imaging time, region of interest)
MISHUM Section 5: human hematopoiesis and immunity
• *Relative human HSC engraftment and chimerism (% huCD45+ cells in
mouse blood at weeks 10, 15, 20 after HCT showing gating strategies)
• Absolute human HSC engraftment and chimerism (absolute numbers of
huCD45+ cells and muCD45+ cells in mouse blood at weeks 10, 15, 20
after HCT showing gating and quantification strategies)
• *Kinetics of human lymphocyte development (% huCD45+, huCD3+,
huCD4+, huCD8+ huCD19+ cells in mouse blood at weeks 10, 15, 20 after
HCT showing gating strategies)
• *Human cytokines or chemokines detectable in plasma at terminal
analyses (ELISA, bead array methods with appropriate human control
samples)
• *Human immunoglobulins detectable in plasma at terminal analyses
(ELISA, bead array methods with appropriate human control samples)
• Kinetics of human myeloid development (% huCD45+, huCD33+,
huCD11c+, huCD11b+, huCD14+ cells in mouse blood at weeks 6, 10, 15,
20 after HCT showing gating strategies)
• Kinetics of human NK development (% huCD45+, huNKp46+, hu56+,
huCD16+ cells in mouse blood at weeks 6, 10, 15, 20 after HCT showing
gating strategies)
• Kinetics of human B cell development (% huCD45+, huCD19+, huCD27+,
huIgM+, huIgG+, huIgA+, cells in mouse blood at weeks 10, 15, 20 after
HCT showing gating strategies)
• Terminal analyses of human hematopoietic cells in lymphatic tissues
(spleen, bone marrow, thymus, peripheral lymph nodes, mesenteric
lymph nodes showing total number of cells recovered by tissue).
• Terminal analyses of human hematopoietic cells in organs (liver, lungs,
brain, etc.. . .).
• Phenotypic characterization of T cells (naïve, central memory, terminal
effector, terminal effector memory)
• Antigen-specific characterization of T cells (ELISpot, intracellular staining
of IFN-c or TNF-a, tetramer analyses)
• Antigen-specific characterization of antibodies produced by B cells
(ELISA, dot-plot, antigen binding by flow cytometry)
• Analyses of antibody functionality against infections (neutralization)
• Immune composition by CyTOF
• Gene expression analyses (microarrays, RNAseq)
MISHUM Section 6: regeneration of human tissues
• Liver engraftment of hepatoblast, hepatocytes and stem cell-derived
cells (ES or iPSC protocols), lung, gut, endocrine pancreas, kidney or other
tissue
• Validation of chimerism in the murine blood (ELISA human albumin
other secreted proteins)
• Functional validation: exogenous test drugs with known and different
human metabolism, viral titers or antigens of human hepatotropic
viruses (HBV, HCV, etc.)
• Validation of chimerism postmortem by immunostaining (human nuclei
or other human-specific antibodies)
• Onset of autoimmunity or diabetes.
MISHUM Section 7: human infections
• *Scientific and informal nomenclature for clinical or laboratory pathogen
isolates
• *Availability through academic collections with material transfer agree-
ment or publicly available through commercial repositories
• Biosafety level containment: BSL-2, BSL-3, BSL-3**, BSL-4
• *Gene modification or reporter gene
• *Route of infection: intravenous, intra-peritoneal, intranasal, intrarectal,
intra-splenic
• *Determination of titer and dose of challenge
• *Analyses of infection dissemination by PCR (primers, methods)
• *Analyses of infection dissemination by histology (antibodies, methods)
Table 1. (continued)
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long-term (20 weeks) multilineage grafts (Notta et al, 2011). Thus,
the quest for the archetypical human HSC population and whether
other defined CD34 HSCs subpopulations should also be consid-
ered for the generation of HIS mice and how to eventually expand
these cells ex vivo without compromising their self-renewal potential
remains to be clarified. Another aspect to be taken in account is that
the ability of human HSPCs to engraft and differentiate into different
hematopoietic lineages may largely depend on their interactions
with the mouse BM microenvironment constituents. As some
human factors may be absent in the mouse BM niche, sponge
scaffolds seeded with human BM-derived mesenchymal stromal
cells (MSCs) have been implanted subcutaneously into NSG mice to
allow the formation of niches for human HSCs to differentiate
(Antonelli et al, 2016; Reinisch et al, 2016; Abarrategi et al, 2017).
Using two-photon microscopy for high-resolution non-invasive
in vivo analyses, these implants are currently enabling the clarifi-
cation of the human BM microenvironment requirements in regulat-
ing human normal and malignant hematopoiesis in vivo (Passaro
et al, 2017).
Another limitation in HIS models is the lack or low levels of
human factors and cytokines in mouse tissues or circulating in the
plasma and needed for human HSC self-renewal or differentiation.
Transgenic expression of human interleukin 3 (IL-3)/granulocyte
macrophage–colony-stimulating factors (GM-CSF)/stem cell factor
(SCF) in NSG mice resulted in enhanced levels of human myeloid
cells and regulatory T cells (Treg) (Billerbeck et al, 2011). Very
promising models are HIS mice generated with a mouse strain
expressing several human cytokines such as macrophage colony-
stimulating factors (M-CSF), IL-3, IL-6, GM-CSF, and thrombopoietin
(TPO), the “MISTRG-6”, and showing improved human T, B, and
NK cell development (Das et al, 2016; Yu et al, 2017). This is a valid
approach, and expression of several different human growth factors
and cytokines to support differentiation of early or mature lymphoid
or myeloid cells has been performed (Rongvaux et al, 2014; Bryce
et al, 2016; Jangalwe et al, 2016). Some recent development was
also exemplified by transgenic expression of human thymic-stromal-
cell-derived lymphopoietin (TSLP) that supported lymph node
development in immunodeficient mice (Li et al, 2018). Dendritic
cells (DCs) are main orchestrators of the adaptive immune system
presenting processed peptide antigens to T cells through MHC
classes I/II and expressing key costimulatory molecules such as
CD40 ligand (CD40L) required for B-cell activation and class switch-
ing (Steinman, 2012). Different types of DCs exist in mice but they
are not homologous to human DCs. Further, in HIS mice, the human
DC development and maturation are not optimal. Novel HIS models
based on the BALB/c Rag2(/) Il2rg(/) Flt3(/) (BRGF) and
NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ Flk2/Flt3/ (NRGF) mice with a
mutated receptor tyrosine kinase Flk2/Flt3 were created. Human DC
development is increased in BRGF and NRGF mice with exogenous
administration of human Flt3 ligand (Flt3L) after HCT, leading to a
major increase also in the numbers of human NK and T cells (Li
et al, 2016; Douam et al, 2018).
A factor to be taken into account for the generation of HIS is the
gender of the mice. Females show better HSC engraftment and faster
human T-cell immune development and maturation (Volk et al,
2017). When setting up these models, it is important to keep in mind
that the kinetics of human immune reconstitution is not linear and
the time of analyses after HCT has to be longitudinally established for
different strains and methods. For example, human T cells show
maturation, activation, and functionality at 15–20 weeks after CB-
HCT in NRG-HIS mice (Volk et al, 2017; Theobald et al, 2018), but
this varies considerably for other HIS models. Future improvements
are seeking a better development of human T cells in HIS mice so that
they will be equipped with functional T-cell receptors (TCRs) able to
interact with the matched HLA complexes on antigen-presenting cells.
This critical advance relies essentially on the substitution of the
mouse MHC class I and II by different HLA haplotypes. To solve this
mismatch problem, a transgenic NRG mouse strain called “DRAG”
• Analyses of pathogenesis (load in different tissues, survival, weight loss,
liver enzymes, virus-induced tumor formation)
• Analyses of infected cells (FACS, FISH, IF, PrimeFlow, single-cell sequenc-
ing)
• Non-invasive optical imaging methods (fluorescence, bioluminescence
substrate, dose, imaging time, region of interest)
MISHUM Section 8: human oncology and immuno-oncology
• *Donor (age, sex, HLA type)
• Primary human tumor or passaged as xenograft
• Isolation or selection method of tumor tissue
• *Tumor information (HLA expression level, exome sequencing,
mutations)
• *Cancer identity and metastasis in vivo by histopathological analyses
• *Autologous or allogeneic to HSCs used in HIS mice
• Characteristics after growth (infiltration and activation of human
lymphocytes)
• Immune modulation of tumor growth
MISHUM Section 9: preclinical testing of human drugs and vaccines
• *Chemical or commercial name
• *Vendor or collaboration agreements
• *Dose, route, schedule
• Pharmacokinetics and pharmacodynamics
• Antibody characteristics for passive vaccination
• Characteristics of attenuated viruses, of antigen carrying receptor target-
ing antibodies, of virus-like particles, and of recombinant viral vaccine
candidates
• Human drug metabolism in the liver: degree of humanization upon test-
ing, next-generation strains with human drug metabolism (PIRF or
other).
• Detection of AST/ALT (liver damage), cytokine release symptom (cytokine
storm)
MISHUM Section 10: testing of human cell therapies
• *Production in laboratory scale, GMP-like or GMP
• *Dose of viable cells
• *Route, schedule
• Pharmacokinetics and pharmacodynamics
• Readouts as described above
MISHUM Section 11: statistical and correlative analyses
• Commercially available statistical software (e.g., t-test, ANOVA, etc.. . .)
• Specialized tests used by professional biostatisticians
• Heat-map analyses
• Principal component analyses
• Neural network analyses
• Isogenic control groups or different donors
Asterisks indicate information that should be required in publications.
Table 1. (continued)
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was developed that expresses HLA-DR4 (Kim et al, 2017). DRAG
mice transplanted with HLA-DR4+ HSCs developed more CD4+ T
cells and higher levels of human immunoglobulins G and M (IgM and
IgG; Kim et al, 2017). HSC-humanized mice expressing class II HLA-
DR4 and class I HLA-A2 transgenes (“DRAGA” mice) generated
CD8+-specific T cells and influenza-specific antibody responses
(Mendoza et al, 2018a). Similarly humanized BRGS mice expressing
human HLA-A2 and DR2 transgenes (BRGSA2DR2) showed faster
development of CD4+ and CD8+ T cells and higher concentration of
IgGs in plasma (Masse-Ranson et al, 2019). The practical limitation
of these HLA-transgenic strains is that it is difficult to find HSCs that
express a particular combination of HLAs.
Another method to improve and accelerate the regeneration of
human T and B cells in HIS mice is the adoptive transfer of gene-
engineered human DCs from the HSC donor that are long-lived
in vivo (Salguero et al, 2014; Daenthanasanmak et al, 2015; Volk
et al, 2017). This approach significantly enhanced the regeneration
of lymph nodes in HIS-NRG mice promoting maturation of functional
human T cells, B cell class switching, and development of antigen-
specific IgGs (Salguero et al, 2014; Daenthanasanmak et al, 2015).
As a take-home message, development of human immunity in HIS
mice depends on several variables (Fig 1A, Table 1). Different
approaches are being taken concurrently to accelerate and optimize
human immune responses in mice. A structured approach to converge
the reporting in scientific publications of the materials and methods
(such as specific mouse strains, sex of the mice, methods used for
HCT, time-points of analyses) will facilitate the interactions in the
community to boost these promising preclinical models (Table 1).
Transplantation and regeneration of different tissues to
study human metabolism
The liver is a vital organ responsible for key metabolic functions
of the body and the site for several human-specific viral infec-
tions. For efficient generation of mice xenografted with human
liver tissues, a combination of a growth disadvantage of the
murine liver and a regeneration stimulus for the human cells is
required. Several approaches resulted in high human liver
chimerism in mice (Dandri et al, 2001; Mercer et al, 2001; Bissig
et al, 2007; Hasegawa et al, 2011) and the resulting models have
pros and cons (reviewed in ref. Bissig et al, 2018). For example,
the transgenic uPA (urokinase-type plasminogen activator
expressed under the albumin promoter) mouse has a profound
dysfunction and triggers apoptosis of murine hepatocytes (Heckel
et al, 1990; Dandri et al, 2001; Mercer et al, 2001). Therefore,
salvage human hepatocyte transplantation is required within 2–
4 weeks after birth. Nevertheless, humanized uPA mice maintain
considerable health problems. Transgenic uPA mice are difficult to
breed, which is also a limitation of another utilized mouse strain
based on NOG mice expressing transgenic herpes simplex virus
type 1 thymidine kinase (HSVtk) under the albumin promoter
(TK-NOG; Hasegawa et al, 2011). Conversely, the metabolic
dysfunction of the Il2rg/ Rag2/ mice with a knock-out for the
fumarylacetoacetate hydrolase gene (FAH/) can be regulated by
a small drug and bred efficiently but the mice frequently develop
murine hepatocellular cancer (Azuma et al, 2007; Bissig et al,
2007). All these models show some remaining mouse liver tissue
that can blur human-specific liver metabolism (Fig 1B, Table 1).
Therefore, next-generation models seek to eliminate the interfering
mouse metabolism. One such model is the POR/ Il2rg/
Rag2/ FAH/ (PIRF) mouse (Barzi et al, 2017), lacking murine
P450 cytochrome function and allowing a human-only cytochrome
metabolism in mice.
Human liver chimeric mice have also been used to model meta-
bolic disorders. The first xenograft model for metabolic liver disease
was established using human hepatocytes from a patient with famil-
ial hypercholesterolemia with a low-density lipoprotein (LDL) recep-
tor deficiency; Bissig-Choisat et al, 2015). It would be desirable to
extend metabolic disease models also to more prevalent disorders
such as non-alcoholic steatohepatitis (NASH). A NASH model would
also require a functional immune system in addition to the liver
chimerism. Such dual humanizations have been achieved previ-
ously (Gutti et al, 2014; Strick-Marchand et al, 2015; Billerbeck
et al, 2016; Dagur et al, 2018). The combined human liver and
immune system models can show formation of fibrosis upon hepati-
tis C virus (HCV) or hepatitis B virus (HBV) infections (Washburn
et al, 2011; Bility et al, 2014).
Another promising approach to study human liver function is the
combination of organoid technology with humanized mouse models
to examine the immune response to regenerative cellular therapies
and cancer. Organoid technology allows the generation of unlimited
numbers of non-malignant (Sampaziotis et al, 2017) or cancer cells
(Broutier et al, 2017; Fig 1B, Table 1). If derived from the same
HSC donor used to humanize the mice, this approach can poten-
tially be used to compare the immunogenicity of autologous and
allogeneic cellular therapies or investigation of safety and efficacy of
autologous cancer immunotherapies.
Studies of type 1 diabetes (T1D) are also prospering with the use
of humanized mice. Backcrossing the insulin 2 (Akita) mutation into
NRG mice (NRG-Akita) followed by human HCT into newborn mice
resulted in > 50% of the NRG-Akita mice rejecting human islet allo-
grafts (Brehm et al, 2010; Fig 1B, Table 1). The Akita model was
also used to demonstrate the efficacy of stem cell-derived human
beta cells (SC-beta) to regulate blood glucose levels in vivo. The
effect of viral infections was also established for studies of T1D,
showing that coxsackievirus B accelerated the destruction of insulin-
producing beta cells of pancreatic islets (Gallagher et al, 2015). HIS
models are currently being developed to recapitulate the course of
disease in human T1D, including the interactions between human
immune system and beta cells (Tan et al, 2017; Walsh et al, 2017).
Recent studies have included engraftment of mice with diverse
hematopoietic and non-hematopoietic human tissues and cell popu-
lations, human-induced pluripotent (iPS) stem cells and embryonic
stem (ES) cell-derived tissues (Shultz et al, 2014). Exciting advances
on the development and use of emerging humanized mouse models
in multiple disciplines are ongoing (Fig 1B, Table 1). Technical and
analytical annotation and standardization strategies to harmonize
the use of human tissues implanted into humanized mice will be
needed (Table 1).
Infections with human-specific pathogens
HIS mice offer a unique possibility to study infectious disease agents
with a tropism toward human leukocytes, hepatocytes, and lung
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epithelia, to characterize the induced immune responses and to
develop therapeutic interventions against associated pathologies
(Fig 1C, Table 1).
One such pathogen is the Epstein–Barr virus (EBV), a common
c-herpesvirus that persistently infects more than 95% of the
human adult population and was the first oncogenic virus identi-
fied in man (Mu¨nz, 2019). Accordingly, it is associated with
around 2% of all malignancies in humans (Cohen et al, 2011).
Despite the threat of primarily B and epithelial cell transformation
in infected individuals, EBV remains asymptomatic in most carri-
ers, presumably due to a near perfect immune control of the virus
by cytotoxic lymphocytes (Taylor et al, 2015). HIS mice can
model this cell-mediated immune control by primarily CD8+ T
lymphocytes (McHugh et al, 2019). EBV infection resulted in
dramatic CD8+ T-cell expansion in humanized mice with a pecu-
liar phenotype (Chatterjee et al, 2019; Danisch et al, 2019). The
expanding CD8+ T cells carried the programmed death receptor
(PD)-1 and T-cell immunoglobulin and mucin domain-containing
protein 3 (Tim-3) but retained cytokine production and were even
superior in cytotoxicity to PD-1 negative CD8+ T-cell populations.
Nonetheless, PD-1 blockade with antibodies did not improve EBV-
specific immune control in HIS mice (Chatterjee et al, 2019). In
contrast, PD-1 inhibition led to elevated EBV titers, increased IL-
10 production, and associated lymphomagenesis. Long-term infec-
tion of HIS mice with another herpes virus, the human cytomega-
lovirus (HCMV) is also possible as human CD34+ cell serves as a
latent reservoir, whereas lytic reactivation in monocytes and
macrophages can be stimulated with granulocyte-colony-stimu-
lating factor (G-CSF) (for a review, see Koenig et al, 2020). HCMV
infection and reactivation result in different immunological
responses and reactivation is associated with a higher PD-1
expression on T cells (Theobald et al, 2018).
Other pathogens that challenge immune compromised humans,
especially pediatric patients after HCT, are human adenoviruses.
Human adenovirus 2 (HAdV2) infection of HIS mice resulted in liver
pathology in one-third of mice, while two-thirds of infected mice
remained asymptomatic (Rodriguez et al, 2017). HIS mice with
asymptomatic HAdV2 infection developed virus-specific IgM and
interferon (IFN)-c-producing T-cell responses. In blood and BM of
mice not showing pathology, only early viral RNA transcripts could
be detected, which suggested the establishment of a persistent infec-
tion. In contrast, severely affected mice showed both early and late
transcripts in many tissues as well as virus production in the liver
(Rodriguez et al, 2017), all signs of disseminated disease, similar to
what is observed in HCT patients that suffer severe HAdV infections
(Lion, 2014).
Viruses for which dichotomous outcomes of infection can be
modeled in HIS mice are the filoviruses of the genus Ebolavirus
(Escudero-Perez et al, 2019). Zaire ebolavirus (EBOV) causes more
than 90% mortality after intra-peritoneal and intranasal infection in
HIS mice (Ludtke et al, 2015; Escudero-Perez et al, 2019). Sudan
ebolavirus (SUDV) causes 70%, Bundibugyo ebolavirus (BDBV)
30%, Tai Forest (TAFV) 20%, and Reston ebolavirus (RESTV) 20%
mortality (Escudero-Perez et al, 2019). Immunopathology with pro-
inflammatory cytokines driven by elevated viral loads in the liver
was observed in the HIS mice that succumbed to RESTV infection
(Escudero-Perez et al, 2019). Thus, HIS mice recapitulate human
susceptibility to five of the six known ebolaviruses.
HIS mice also offer platforms to explore new therapeutic
avenues. This has primarily been investigated for human immunod-
eficiency virus (HIV; Marsden & Zack, 2017). For example, treat-
ment of HIV infection with broadly neutralizing antibodies (bNAbs)
was established in HIS mice (Klein et al, 2012). These studies
primarily explored antibodies against four regions of the HIV
envelope protein that consists of three heterodimers of glycoprotein
(gp)41 and gp120 (Caskey et al, 2019). These four regions are the
CD4 binding site, the V3 loop, the membrane proximal region, and
the V1/V2 region. In these bNAb treatment studies, mutational
escape from single bNAb treatment of viremic HIS mice was
observed, while mixtures of several bNAbs were able to suppress
HIV viral titers for several weeks (Klein et al, 2012). Based on these
successful treatments in HIS mice and control of hybrid simian and
human immunodeficiency virus (SHIV) in macaques (Nishimura
et al, 2017), HIV-specific bNAbs were also tested in patients with
and without prior anti-retroviral therapy (ART; Caskey et al, 2015,
2017). Similar to HIS mice, individual bNAb treatment suppressed
HIV viremia only transiently with escape mutation development.
Even transfer of two bNAbs only achieved suppression in HIV-
infected individuals after prior ART treatment (Bar-On et al, 2018;
Mendoza et al, 2018b). Thus, multiple bNAbs probably need to be
maintained at sufficient plasma levels to suppress HIV long term in
HIS mice and patients.
Improving T cell-mediated immune control of HIV through gene
therapy is another avenue that is explored in HIS mice. Studies fall
into two main categories, either improving T-cell reactivity by HIV-
specific TCR and chimeric antigen receptor (CAR) expression or
rendering T cells resistant to HIV infection (Carrillo et al, 2017). For
improving T-cell function, HIV-specific TCRs were introduced in
HSCs and could suppress HIV infection (Kitchen et al, 2012). As
another strategy, in order to target cells replicating HIV and with
gp120 surface expression, an extracellular domain of CD4 fused to
the CD3f signaling domain was expressed in T cells (Zhen et al,
2015, 2017). Downregulation of the HIV co-receptor, a chemokine
receptor targeted by R5 tropic HIV strains (CCR5), has primarily
been explored. HIV infection in HIS mice could be significantly
compromised by CCR5 deletion or downregulation by zinc finger
nuclease-mediated gene editing or RNA silencing, respectively (Holt
et al, 2010; Myburgh et al, 2015; Shimizu et al, 2015). The long-
term survival of such engineered T cells might potentiate a func-
tional cure of HIV, but also raises concerns with respect to toxicities
and adverse effects of the respective cellular products, which can be
assessed in HIS mice.
Engraftment of additional human tissues, like liver, bone, lung,
and thymus, has been reported, but mainly hepatocytes and human
lung tissue have been explored for infections with human patho-
gens. For example, humanized liver mouse models have been used
to study infections by different hepatitis viruses (Dandri et al, 2001;
Mercer et al, 2001; Bissig et al, 2010; Lutgehetmann et al, 2012;
Allweiss et al, 2016). However, simultaneous reconstitution of
human tissues with autologous human immune cells remains a
challenge. Nevertheless, HBV and HCV infections have been
explored in HIS mice with allogeneic or autologous hepatocyte
engraftment (Washburn et al, 2011; Billerbeck et al, 2016; Dusseaux
et al, 2017). More recently, bone marrow, liver, and thymus (BLT)
engrafted mice have also been combined with ectopic human lung
transplants (Wahl et al, 2019). Intra-organ infection of these
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animals with different human-specific viruses (Middle East respira-
tory syndrome-related coronavirus (MERS), Zika virus, respiratory
syncytial virus (RSV), and HCMV) showed virus replication within
lung implants, as well as antigen-specific humoral and T-cell
responses. Further studies in this direction are necessary to widen
the application of humanized mice to additional human pathogens
and immune responses against them.
These examples of the use of humanized mice to recapitulate
human infections and associated immune responses illustrate the
vigor and translational value of these models. Standardization of the
reporting will improve the interpretation of results for single infec-
tions and for cross-reference among the different pathogens studied
(Table 1).
Cell line- and patient-derived xenografts for human
oncology research
Over the past decades, mouse xenograft models have significantly
contributed to a better understanding of human malignancies.
Cancer-derived immortalized cell lines can adapt to in vitro growth
and do not replicate the original malignant physiology seen in
patients, potentially leading to artifacts in oncology studies. Thus,
patient-derived xenograft (PDX) models are currently the state-of-
the-art approach. Development of liquid and solid PDX models relies
on the availability of material obtained from patients with defined
types of cancer, which after minimal manipulation is transferred by
several routes into immunodeficient mice (Fig 1D, Table 1). Never-
theless, whereas cell line-based xenografts allow an easier standard-
ization of models, PDX samples are highly variable, can adapt to the
murine environment and the human tumor stroma can be eventu-
ally replaced by murine cells.
For leukemia research, while the generation of immunodeficient
mouse strains like NSG has enabled functional in vivo studies on
human hematopoiesis, engraftment of (in particular) myeloid malig-
nant cells has remained challenging. The absence of a human bone
marrow niche and species-specific growth factors underlies these
challenges, and most notably, it has been difficult to maintain self-
renewal properties of malignant stem cells. Since these populations
are thought to be the therapy-resistant cells that frequently cause
relapse of disease, it is of critical importance to use xenograft
models in which specifically these cells can be propagated and stem-
ness maintained. In order to further humanize xenograft models,
transgenic and knock-in strains have been generated that (over)ex-
press growth factors like IL-3, GM-CSF, SCF, TPO, and/or M-CSF, as
well as others (Wunderlich et al, 2010; Rongvaux et al, 2014). An
alternative approach has been to develop a human microenviron-
ment in the mouse initiated by mesenchymal stem cells coated on
3D scaffolds (Antonelli et al, 2016; Abarrategi et al, 2017; Carretta
et al, 2017) or embedded in matrigel (Reinisch et al, 2016). These
models have allowed the engraftment of various hematological
malignancies, including those that are notoriously difficult to engraft
in regular NSG models such as low-risk acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS), and myelofibrosis.
Importantly, self-renewal was better maintained in these models as
shown by serial transplantation experiments and transcriptome
studies. As such, these models more faithfully capture the disease
phenotypes as seen in human patients and therefore are likely to
produce more clinically relevant and translatable results when used
in drug screens. A challenge that remains is that myeloid malignan-
cies, in particular AML, display a complex clonal heterogeneity.
Multiple genetically distinct subclones can co-exist within an indi-
vidual patient, each driven by a similar founder mutation but with
different secondary driver mutations. These clones are not only
genetically distinct; they also differ remarkably at the transcriptome,
epigenome, and cell biological level (de Boer et al, 2018). To
develop curative therapies, this clonal heterogeneity needs to be
taken into account. It has become clear that not all clones of an indi-
vidual patient might engraft equally efficiently in mice, and also the
level of humanization of the model used might impact on whether
the true clonal heterogeneity is preserved in vivo (Klco et al, 2014;
Antonelli et al, 2016; Carretta et al, 2017; Wang et al, 2017; de Boer
et al, 2018). Both (deep) sequencing technologies and flow cytome-
try-based approaches are useful tools to dissect clonal heterogeneity,
in vitro as well as in mouse models. For instance, an “infinicyt”-
based approach, which combines expression profiles of multiple
aberrant AML-specific plasma membrane proteins, can provide
subclone-specific insights into the clonal complexity of the malig-
nancy under study (de Boer et al, 2018). Implementation of such
technologies is warranted in any conducted in vivo xenograft experi-
ment to link drug responses to specific genetic features of malignant
clones.
In the case of solid tumors, the use of PDXs for preclinical
drug development holds potential to improve our knowledge of
the principles underlying responsiveness to individualized treat-
ment regimens (Hidalgo et al, 2014; Byrne et al, 2017). Yet, many
questions are still open, in particular concerning the ability of the
PDX approach to directly influence clinical decision making
(Aparicio et al, 2015). Not all cells that compose the parental
tumor successfully engraft in the mouse, which introduces a
selective pressure for genetic variants conferring better survival
fitness (Ben-David et al, 2017). The subsequent propagation steps
may also affect clonal dynamics, with further deviation of serially
passaged samples from the primary tumor from which they were
derived (Eirew et al, 2015). The lack of a fully functional immune
system in the host and the fact that human stromal components
—such as cancer-associated fibroblasts, endothelial cells, and
inflammatory cells—are replaced by murine counterparts add
extra layers of divergence over native tumors (Hidalgo et al,
2014; Aparicio et al, 2015; Byrne et al, 2017). These limitations
notwithstanding PDX models of solid tumors offer considerable
opportunities for biomarker and target nomination. First, although
serially passaged PDXs are likely to be genetically different from
the matched tumor of their donor patients, they are expected to
display genomic makeups and polyclonality patterns that, on a
probabilistic basis, may be similar to those of tumors that sponta-
neously develop in unrelated individuals (Eirew et al, 2015; Byrne
et al, 2017). These factors make PDXs critical tools in the transla-
tional oncology domain, whereby predictive biomarkers discov-
ered in PDXs may be leveraged for the prospective identification
of patients with tumors exhibiting the same biomarker repertoire.
Second, responses to therapies that target driver oncoproteins are
thought to be only partly influenced by microenvironmental
parameters and more directly dependent on cancer cell-intrinsic
features, which affords results in PDXs with adequate predictive
power for cancer cell-directed treatments (Byrne et al, 2017).
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Finally, vast PDX collections are poised to capture inter-patient
tumor diversity on a population scale, thus representing power-
ful platforms for large-scale genotype–response associations (Gao
et al, 2015).
The above examples illustrated the importance of PDX models in
understanding the evolution of tumor growth, investigating the
mechanisms of drug resistance, and developing personalized treat-
ments. Critical to these studies is ensuring researchers have access
to high-quality PDX models and molecular datasets that give suffi-
cient power to perform informative analyses. However, the complex
nature of PDX models and the heterogeneous resources that gener-
ate them often lead to crucial information about tumors, host
strains, transplant, and quality assurance processes being inconsis-
tently presented. To address this challenge, the PDX research
community developed the PDX Model Minimal Information stan-
dard (PDX-MI) that defines the critical metadata needed to exchange
knowledge about PDX models (Meehan et al, 2017). PDX-MI
describes the clinical attributes of a patient’s tumor, the processes of
implantation and passaging of tumors in a host mouse strain, qual-
ity assurance methods, and the use of PDX models in cancer
research. Since its inception, PDX-MI has been adopted by produc-
ers of PDX models including the international PDXNet and EurOPDX
consortia as well as the PDX Finder Catalog that captures, harmo-
nizes, and disseminates data about PDX models and associated
Omic datasets (Conte et al, 2019). PDX-MI promotes reuse of
models and data, maximizing the impact of these models on oncol-
ogy research and facilitating the development of new treatments.
Human immuno-oncology research
Therapeutic modulation of the human immune system to improve
recognition and response to tumors is a clinically accepted revolu-
tion in oncology treatment for multiple tumor types (Pardoll, 2012).
Immuno-oncology (IO) is considered a breakthrough due to signifi-
cant and durable tumor regression coupled with increased long-term
survival. However, these clinical responses only occur in a subset of
patients. Therefore, considerable investment in preclinical research
is still necessary to identify new and improved approaches to cancer
cell-specific immune response as well as testing of combinatorial
strategies. These and other approaches are typically developed in
syngeneic mouse models of oncology to work out mechanisms of
action. Nonetheless, human-specific immune modulators require
in vivo models with human-specific targets on both human immune
cells and human tumors to validate preclinical responses, accelerate
development, and improve translation to the clinic. Ideally, IO
in vivo studies will rely on the combination of HIS and PDX models.
As described in the following sections, HIS mice co-engrafted with
human tumors are proving to be a valuable tool in the development
of new strategies for human-specific immuno-oncology therapies.
Nonetheless, as these models are per se complex and the matching
of the tumor and immune system from the same patient is currently
a difficult task, several studies explore cell line derived xenograft
(CDX) implanted after humanization in HIS mice or administration
of human peripheral blood lymphocytes (PBL; Fig 1E, Table 1).
These IO studies have been used, for example, to test immune
modulation caused by engineered agonistic or antagonistic mono-
clonal antibodies (mAb; Scott et al, 2012), bispecific T-cell engagers
(BiTE; Baeuerle & Reinhardt, 2009), or T-cell bispecific antibodies
(TCB; Bacac et al, 2018).
A very important and commonly asked question regarding
human tumor cell engraftment in HIS mice is whether the CDX or
PDX tumor and hematopoietic donor must be 100% HLA-matched
to allow co-engraftment. Neonatal irradiated NSG mice co-injected
into the liver with CD34+ cord blood-derived HSC and HLA-
mismatched human breast CDX, resulted in the development of a
human immune system together with human tumor growth, includ-
ing metastases in the lung and brain (Wege et al, 2011, 2014).
Tumors were partially infiltrated with T cells, B cells, and myeloid
cells. More detailed analyses of the spleen revealed not only a T-cell
specific activation pattern but also B-cell maturation and the produc-
tion of tumor-specific antibodies (Wege et al, 2014). Moreover, the
tumor engrafted HIS mice were used for a preclinical trial to test the
potential of IL-15 in combination with trastuzumab (anti-HER2
mAb) therapy with the intention to enhance antibody-dependent
cellular cytotoxicity (ADCC; Wege et al, 2017). IL-15 treatment trig-
gered immune activation and promoted tumor depletion but also
induced systemic inflammation, resulting in death of the treated
mice (Wege et al, 2017).
In another study, 3-week-old NSG mice were engrafted with cord
blood-derived CD34+ HSC first to establish mature multilineage
immune engraftment and then injected subcutaneously 12–
16 weeks later with partially HLA-matched PDX tumors (Wang
et al, 2017). Despite the presence of a wide range of functional
immune cells, the HIS mice were capable of engrafting the tumors
and in many cases the growth kinetics of these tumors did not vary
significantly from immunodeficient controls not engrafted with HSC.
However, not all partially HLA-matched tumor/HSC donor combina-
tions escape immune-mediated changes in growth kinetics and some
tumors are rejected, highlighting the importance of empirically test-
ing tumor growth against multiple HSC donors. Subcutaneously
engrafted tumors were infiltrated with a wide range of human
innate and adaptive immune cells and both the frequency and distri-
bution of immune cell types varied across different tumor types
(Wang et al, 2017). One mechanism known to prevent T cells from
responding to tumors is the PD-1 and its ligand (PD-L1) checkpoint
pathway. The clinically approved checkpoint inhibitor pembroli-
zumab (anti-PD-1 mAb) has been tested in tumor-bearing HIS mice
and suppression of tumor growth was observed using both CDX and
PDX tumors (Wang et al, 2017). Suppression of tumor growth with
pembrolizumab only occurred in mice co-engrafted with human
immune cells and the response was abrogated when mice were
pretreated with anti-human CD8 mAb to deplete human CD8+ T
cells, demonstrating human CD8+ T cells mediated the effector
response following release from checkpoint inhibition. Efficacy stud-
ies with pembrolizumab were run with multiple HSC donors distrib-
uted among both control and treatment arms of each tumor tested
for response. Multiple HSC donors allowed the observation that not
all tumor/HSC combinations show a response to pembrolizumab,
and the frequency of donor-related response (~ 25–30%) is similar
to what is observed in the clinic (Topalian et al, 2012).
Regulatory T cells (Tregs) infiltrate a wide range of tumor types
and mechanism of action studies performed in syngeneic mouse
tumor models revealed that depletion of these cells from the tumor
could release T effector cells from Treg suppression (Smyth et al,
2014). Preclinical efficacy for this approach was demonstrated when
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HIS mice were engrafted with SK-MEL-5 human melanoma CDX and
treated with an anti-human mAb targeting the glucocorticoid-
induced TNFR family-related (GITR) protein, highly expressed on
Tregs. Tumor growth was significantly suppressed, the percentage
of Tregs was reduced in tumor and spleen, and tumor-infiltrating
lymphocytes showed increased secretion of the effector cytokines
IL-2 and IFN-c (Mahne et al, 2017).
As more IO treatments move through clinical trials, clinicians
are seeing an association between strong immune-mediated tumor
killing responses and cytokine release syndrome (CRS). Given
these observations, preclinical studies able to recapitulate CRS in
HIS mice are becoming highly relevant. In a recent report, HIS
mice were co-engrafted with a diffuse large B-cell lymphoma
(WSU-DLCL2) and treated with either obinutuzumab (anti-CD20
mAb) or a novel CD20-T-cell bispecific antibody (TCB) containing
two CD20 binding domains and one CD3e domain in a head-to-tail
orientation to one of the CD20 regions (Bacac et al, 2018). CD20-
TCB promoted a more extensive killing response than obinu-
tuzumab. Further, CD20-TCB administration was associated with
increased expression of multiple human inflammatory cytokines
indicating a CRS response that was not observed with obinu-
tuzumab treatment. An alternate strategy was tested where treat-
ment was initiated with a single dose of obinutuzumab followed
by multiple high doses of CD20-TCB. The pretreatment with obinu-
tuzumab strategy enabled rapid and extensive tumor killing with
minimal CRS response. These types of preclinical experiments with
HIS mice demonstrate their value in working out protocols
designed to maximize both efficacy and safety.
The question of immuno-therapy-mediated toxicity, particularly
in the context of CRS, is a key component of preclinical evaluation
and a reliable assay is needed. Neither in vitro assays nor non-
human primates have proven reliable for assessment of CRS (Steb-
bings et al, 2007). A team at the US Food and Drug Administration
recently published two reports testing CRS using mAb therapies
known to have a strong cytotoxic response in the BLT-HIS mice
(Yan et al, 2019a,b). BLT mice were injected with adalimumab
(anti-TNF-a mAb) as a negative control because it is used clinically
without evidence of CRS. The test article was TGN1412 (anti-CD28
mAb), a reagent known to be associated with clinical CRS.
TGN1412-treated BLT mice released multiple cytokines into periph-
eral blood within 2-4 hours of treatment, indicating a strong CRS
response that was not observed in the adalimumab-treated group
(Yan et al, 2019a). The mice also showed a decrease in human
CD45+, CD3+, CD4+, CD8+, and CD19+ cells in peripheral blood
similar to human patients and showed an increase in murine serum
amyloid A, indicating severe liver inflammation. A second study
compared muromonab (anti-CD3 mAb, OKT3) to adalimumab in
BLT mice. The muromonab-treated mice released multiple proin-
flammatory cytokines associated with CRS into peripheral blood
within 2–4 h, and pretreatment of mice with methylprednisolone
prior to muromonab blunted or delayed development of CRS (Yan
et al, 2019b). Together, these studies show that BLT-HIS mice are
capable of recapitulating multiple aspects of a strong CRS response
when dosed with mAb therapies designed to stimulate strong T-cell
activation.
To our knowledge, no direct comparisons between PBMC-HIS
and BLT-HIS model mice have been made to date. There are
several published studies using PBMC-HIS mice demonstrating CRS
(Brady et al, 2014; Weissmuller et al, 2016) with the mice being
used between 6 and 16 days of PBMC injection. In both reports,
the authors state there were no signs of GVHD present when used.
In Yan et al (2019a), a limited comparison of CD34-HIS mice and
BLT-HIS mice was undertaken and BLT-HIS mice showed clear
evidence of CRS and no GVHD, whereas CD34-HIS mice did not
show any difference as compared to control treatment, suggesting
that the CD34-HIS mouse does not show a clear signal for CRS and
may not be an appropriate model. As previously published for the
BLT-HIS mouse (Weaver et al, 2019), when present, GVHD is
clearly evident and can be differentiated from other processes, such
as CRS. GVHD occurs rapidly and for all PBMC-HIS mice, but does
not occur with high frequency in BLT-HIS mice. With respect to
CRS, PBMC-HIS mice would potentially demonstrate CRS for drugs
specifically impacting T cells, but not other tissues or cell types.
BLT-HIS mice have much broader engraftment in terms of cell
types and presence in non-lymphoid organs, suggesting that a
wider range of targets could demonstrate CRS if present. For
preclinical use, the Stebbings in vitro assay (Stebbings et al, 2007)
should be initially undertaken. Studies with HIS mice would be
adjunctive and informed by both the target of the therapeutic and
what organ system(s) were targeted. Additional circumstances in
which in vivo testing could be helpful include higher risk drug
targets and non-T-cell targets.
In conclusion, HIS mice are a powerful tool for IO research. HIS
mice do not recapitulate every aspect of human immunity, but they
are capable of answering a wide range of important scientific ques-
tions that form a critical guide for preclinical IO discovery. Future
challenges will include the understanding of the donor-to-donor
immune variability observed in some of these treatment strategies.
This will provide opportunities to identify predictive markers and
clinical diagnostics assays helpful in assisting patient enrollment for
improved treatment outcomes. Tumor populations that escape
response in subsets of mice can be further analyzed for understand-
ing mechanism of resistance.
Minimal information for standardization of
humanized mice
Humanized mouse models result from the sum of several compo-
nents: choice and availability of human donors, human cells or
tissues, mouse recipient, types of manipulations, human infections,
and human tumor types. Furthermore, the materials available for
analyses and methods of analyses provide another level of complex-
ity. It is quite clear that humanized mouse models are customized
by the different laboratories around the globe and it would be unre-
alistic to standardize how the models should be built. Nevertheless,
reporting of minimal information provided by specific guidelines
can facilitate independent validation of published data, which is a
fundamental cornerstone for scientific advancements. The list of
variables provided in Table 1 is an initial attempt brought up by the
faculty participating in the 2017 and 2019 EMBO Practical Courses
created for training young investigators on the development of
humanized mouse models.
This initiative called “Minimal information for standardization of
humanized mouse models” (MISHUM) is built on the experience of
the authors of this manuscript in developing similar reporting
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standards for non-humanized PDX models (Meehan et al, 2017).
The main aim of this workgroup is, similar to PDX-MI, to promote
material and protocol exchange, transparency in reporting of assays
and analyses performed. The standards described here represent a
starting point. The longer term intention is to extend this initiative
beyond the EMBO courses to include input from multiple stakehold-
ers from both academia and industry. Further, in order to enable a
standardized interpretation of already published results, the collec-
tion of technical information and quantifiable data can in the future
be procured within MISHUM for the creation of a digitalized data-
base. Once these standards and database are evolving, a parallel
data mining activity will provide the opportunity to explore and
discover convergent signatures and patterns of human immunology,
infections, and oncology in vivo in humanized mice. Our long-term
goal is that, in the future, these models will become largely repro-
ducible and predictive models for the understanding of human phys-
iology, immunology, and oncology, which require a living
experimental system. Beyond the gain of scientific information,
we hope to make humanized mouse models more environmen-
tally sustainable by optimizing the methods and reducing the
number of humanized mice used for experimentation. Ultimately,
we seek to support the “3R” principles: (i) Replace the use of
humanized mice if alternative in vitro techniques (such by the
use of organoids or chips), metadata or data mining eventually
prove to be as solid as the in vivo results; (ii) reduce the number
of humanized mice to a minimum within each experimental
cohort; and (iii) refine the experimental setup using the best and
ethically available human material and analyses, also making
sure that invasive approaches can be minimized to mitigate the
suffering of the animals. Only with a consensus checklist and
with a coherent reporting policy, we will be able to identify the
best material, methods, and analyses that will ultimately lead to
optimized humanized mouse models.
Pending issues
Below is a summary of main topics identified by our community
that remain to be solved on a case-by-case basis depending on the
use of the humanized mouse model:
Human hematopoiesis and immunity: Methods to expand human
HSCs will enable larger experimental cohorts. Novel methods for
matching the HLA between human hematopoietic cells and mouse
epithelial cells will improve human T-cell development in a HLA-
restricted manner. Better development of lymph nodes and germinal
centers within the spleen that would improve innate and adaptive
immune responses. Novel mouse strains or methods allowing regen-
eration of lymph nodes will allow B cell class switch and production
of human high-affinity IgG and IgA antibodies.
Human metabolism: Mice and human display different rates and
pathways of metabolism, and particularly for liver metabolism, it
is essential to address this limitation of humanized mice. Since
many metabolites are diffusible, new models are needed that can
eliminate or temporarily block murine metabolism while using
chimeric mice.
Human infections: Engraftment of human peripheral tissues (i.e.,
liver, lung, skin, and brain) will allow infections with human
pathogens targeting other tissues than immune cells, and the
possibility of combining them with HLAs matched human
hematopoietic stem cells will create a more complete model of
human infection. Better engraftment of the human erythrocyte
lineage will allow further studies of erythrocyte-infecting patho-
gens (i.e., plasmodium).
Human oncology: Further humanization of xenograft mouse models
such as implantation of human MSC-coated 3D scaffolds or NSG
mice (over) expressing human cytokines has improved engraftment
rates of primary tumor cells. However, for each individual cancer
patient case, it will have to be established which (sub)clones prefer-
ably grow out. Also, it will need to be carefully evaluated how the
transcriptome and epigenome of the original patient samples are
preserved in the PDX models.
Human immuno-oncology: The HLA matching of the human
immune system and tumor will be required. A functional enhance-
ment of the CD4+ and CD8+ T cells will be needed to allow higher
tumor infiltration and anti-tumor responses. An improved and faster
development of “avatar” PDX models will allow decisions about
personalized therapeutic options.
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In this Special Issue “Humanized Mice in Vaccinology: Opportunities and
Challenges”, aspects related to the use of humanized mice in vaccinology,
opportunities, and the challenges ahead are discussed.
(iv) http://www.pdxfinder.org/pdx-standard/ The PDX Minimal Information
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